enGene
Ryan Daws has a strong background in finance and investment banking. Ryan has held various executive roles throughout their career, including Chief Financial Officer positions at enGene, Obsidian Therapeutics, and Concert Pharmaceuticals, Inc. Prior to these roles, Ryan worked as a Managing Director at Baird, where they focused on healthcare investment banking. Ryan also gained extensive experience at Stifel Nicolaus and Cowen and Company, LLC, where they served as a Director and was responsible for generating new business and executing deals within the life sciences and specialty pharmaceutical sectors. Ryan has a successful track record of developing and maintaining senior-level relationships and providing strategic financial advice to clients.
Ryan Daws completed their Bachelor of Science degree in Finance and Organizational Management at the University of South Carolina from 1992 to 1996. Subsequently, they pursued an International Master of Business Administration with a focus on International Business and Finance from the University of South Carolina Darla Moore School of Business between 1996 and 1998.
This person is not in any teams
This person is not in any offices
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications